NanoMedSyn was born from the fundamental research of its biologist and chemist founders who discovered a breakthrough technology for drug delivery to the lysosomal cell compartment leading to potentiation of therapeutics. This technology, validated at the preclinical level, has a wide range of applications in the fields of oncology, immunity, inflammation or metabolism. NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA. The main application is the engineering of recombinant proteins like antibodies or enzymes for better therapies.
Looking for a particular NanoMedSyn employee's phone or email?
The NanoMedSyn annual revenue was $1 million in 2026.
Marcel Garcia is the CEO of NanoMedSyn.
4 people are employed at NanoMedSyn.
The NAICS codes for NanoMedSyn are [541, 541713, 5417, 54, 54171].
The SIC codes for NanoMedSyn are [873, 87].